These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38777864)

  • 1. Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the US.
    Flanigan JA; Yasuda M; Chen CC; Li EC
    Support Care Cancer; 2024 May; 32(6):373. PubMed ID: 38777864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs associated with febrile neutropenia in the US.
    Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
    Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
    Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
    J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma.
    Li S; Liu J; Bowers C; Garawin TAFS; Kim C; Bensink ME; Chandler DB
    Support Care Cancer; 2020 Jan; 28(1):113-122. PubMed ID: 30993450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis.
    Aslam S; Li E; Bell E; Lal L; Anderson AJ; Peterson-Brandt J; Lyman G
    J Manag Care Spec Pharm; 2023 Feb; 29(2):128-138. PubMed ID: 36705281
    [No Abstract]   [Full Text] [Related]  

  • 6. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
    Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
    J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
    Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
    Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare resource utilization and costs associated with hepatitis A in the United States: a retrospective database analysis.
    Samant S; Chen E; Carias C; Kujawski SA
    J Med Econ; 2024; 27(1):1046-1052. PubMed ID: 39092467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare resource utilization and direct medical costs associated with index and recurrent
    Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
    J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children.
    Raisch DW; Holdsworth MT; Winter SS; Hutter JJ; Graham ML
    Value Health; 2003; 6(2):158-66. PubMed ID: 12641866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost of the inpatient management of febrile neutropenia in cancer patients--a micro-costing study in the Irish healthcare setting.
    O'Brien C; Fogarty E; Walsh C; Dempsey O; Barry M; Kennedy MJ; McCullagh L
    Eur J Cancer Care (Engl); 2015; 24(1):125-32. PubMed ID: 24472035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
    Boccia R; Glaspy J; Crawford J; Aapro M
    Oncologist; 2022 Aug; 27(8):625-636. PubMed ID: 35552754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with liver and/or lung disease: a longitudinal retrospective study in the USA.
    Hagiwara M; Divino V; Munnangi S; Delegge M; Park S; Marins EG; Ren K; Strange C
    J Comp Eff Res; 2024 Jun; 13(6):e230186. PubMed ID: 38696696
    [No Abstract]   [Full Text] [Related]  

  • 15. Febrile Neutropenia in Patients with Solid Tumors Undergoing Intravenous Chemotherapy.
    Moreira-Pinto J; Leão I; Palmela C; Branco F; Godinho J; Simões P; Leal-Costa L; Lopes F; Faria A; Casa-Nova M; Escária A; Costa F; Galvão I; Teixeira J; Passos-Coelho JL
    Oncol Res Treat; 2020; 43(11):605-612. PubMed ID: 32818937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of direct medical costs of hospitalization for febrile neutropenia.
    Lathia N; Mittmann N; DeAngelis C; Knowles S; Cheung M; Piliotis E; Shear N; Walker S
    Cancer; 2010 Feb; 116(3):742-8. PubMed ID: 20029970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.
    Gebremariam GT; Fentie AM; Beyene K; Sander B; Gebretekle GB
    BMC Health Serv Res; 2022 Dec; 22(1):1600. PubMed ID: 36585648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors.
    Weycker D; Li X; Edelsberg J; Barron R; Kartashov A; Xu H; Lyman GH
    J Oncol Pract; 2015 Jan; 11(1):47-54. PubMed ID: 25491042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
    Naeim A; Henk HJ; Becker L; Chia V; Badre S; Li X; Deeter R
    BMC Cancer; 2013 Jan; 13():11. PubMed ID: 23298389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.